Fulgent Genetics : Investor Presentation PDF

Published: 2025-05-02 08:39:55 ET FLGT

Published on 05/02/2025 at 08:39

May 2, 2025

Founded in 2011 | Located in El Monte, CA | NASDAQ:FLGT

Leadership Team

Ming Hsieh

Paul Kim

Dr. Harry Gao

James Xie

Brandon Perthuis

Natalie Pre scott

Dr. Ray Yin

Chief Executive

Chief Financial

Lab Director and

President and

Chief Commercial

General Counsel &

President, Pharma

Officer

Officer

Chief Scientific

Chief Operating

Officer

Chief Privacy Officer

Officer

Officer

Experie nce d operational lead er, en tre preneu r a nd phila nth ropist

Pre viou sly CEO, Pre side nt, and Chairman of Cogent Systems, Inc.

Member of the National Academy of Eng ineering ; Fellow of the Nationa l Academy of Inventors; Truste e of USC

Experie nce d finan cial

lead er and Certified Pub lic

Accountant

Pre viou sly CFO of Coge nt Systems, Inc.; so ld to 3M for $943M in 2010

B.A. in Econo mics from University of California at Ber kele y

Pre viou sly Lab Dir ector at

City of Hope

Clinical mole cula r g enetics training fellowship and postdoctoral fellowship at Harvard Medical Sch ool

M.S. in Immun ology, and

M.D. and Ph.D. in Microbiolog y, Immunolo gy, and Medical Gen etics

Responsible for managing all glob al o perations, pr oduct vision and product

eng ineering

Served as an SVP of Cogent

Systems, Inc.

B.A. in Engineering, M.S. in

Industrial Enginee ring and an

M.S. in Computer Science

Extensive experie nce lea ding gen etic testing commercializa tion pr ograms since 2 003

Pre viou sly VP of Sale s and Marketing of the Medical Ge netics Labora tor y at Baylor College of Me dicin e

B.S. in Bio me dica l Science

Prio r to Baylor, held se nior role s at P erkinElmer, Inc. an d Spe ctral Gen omics, Inc.

Sea son ed legal and privacy pro fessional with nea rly two decade s of le gal exp erience

Privacy La w Specialist; Certifie d Information Privacy Manag er; Certified Information Privacy

Pro fessional and an Advisory Boa rd Memb er with the International Associa tion of Privacy Pr ofessionals

J.D. from Duke University

School of Law

Founde r & CEO, ANP Technologie s, Inc.

Former Team L eader of Nanobio techno logy for Chem/Bio Defense, U.S. Army Resear ch Lab oratory

Holder of 46 drug delivery/detection pa ten ts

3

About Fulgent

We are a premier global, technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health.

Develop flexible and affordable diagnostics and therapeutics that improve the everyday lives of those around us.

Innovation

Customer Service and Commitment

Quality and Efficiency

Our People

Leverage our proprietary technology platform for

broad application

Further clinical/regulatory program for Pharma

Operational excellence

Disciplined M&A 4

To build a vertically integrated solution to combat cancer

early detection | clinical diagnostics | post treatment monitoring | drug discovery and cancer treatment

Strategic Vision - A One-Stop Solution for Cancer Care

Leading Genetic Testing Company Offering Tech-Enabled Diagnostic Solutions

Exciting Cancer Therapeutic Opportunity Realizing Precision Medicine Potential

Vertically integrated "one-stop" solution across the healthcare chain following the CSI, Inform Diagnostics, and Pharma acquisitions

Proprietary nano drug delivery technology platform serves as an underpinning technology between diagnostic and pharm to help create a more sustainable and profitable business model in precision medicine for years to come

Addition of a talented scientific team creates a strong synergy and competitive advantage that may be leveraged across the combined business

Potential near-term opportunity includes shortened 505(b)(2) drug development and commercialization timelines and potential long-term opportunity leverages large data insights and novel analytical tools from diagnostics business to enable additional precision medicine pipeline through organic or partnered development strategies

Commitment to continue growing diagnostic and therapeutic opportunities through organic investments and M&A

Seasoned management team along with strong cash position allow Fulgent to enter therapeutic opportunities while managing risk

5

Disclaimer

Fulgent Genetics Inc. published this content on May 02, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 02, 2025 at 12:35 UTC.